Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT01485614
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT01485614 -
2011-002528-42
-
- Other papers using this trial's data
- A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01485614. Randomized; double masking; primary purpose treatment. Start 2012-02-10 (actual); primary completion 2019-10-09 (actual). Results posted on 2020-12-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)
- Condition
- Diabetes Mellitus
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo to sitagliptin
- Intervention (Drug)
- Placebo to metformin
- Intervention (Drug)
- Glycemic Rescue 1
- Intervention (Biological)
- Glycemic Rescue 2
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01485614- Content hash
e0a002dfbb36d80128e3518fb11d74146e3373bf27a8dc671d9152e794ca4b3e